We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed the most recent trading day at $209.17, moving -0.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.77%. At the same time, the Dow added 1.42%, and the tech-heavy Nasdaq gained 2.28%.
Heading into today, shares of the drugmaker had gained 3.92% over the past month, outpacing the Medical sector's loss of 1.17% and the S&P 500's loss of 5.73% in that time.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. The company is forecasted to report an EPS of $2.51, showcasing an 8.66% upward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $12.92 billion, up 4.94% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $12.30 per share and revenue of $59.52 billion, indicating changes of +21.54% and +5.66%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.02% lower. At present, AbbVie boasts a Zacks Rank of #3 (Hold).
Looking at its valuation, AbbVie is holding a Forward P/E ratio of 17.07. This expresses a premium compared to the average Forward P/E of 14.53 of its industry.
Also, we should mention that ABBV has a PEG ratio of 1.43. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.34.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 69, positioning it in the top 28% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
AbbVie (ABBV - Free Report) closed the most recent trading day at $209.17, moving -0.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.77%. At the same time, the Dow added 1.42%, and the tech-heavy Nasdaq gained 2.28%.
Heading into today, shares of the drugmaker had gained 3.92% over the past month, outpacing the Medical sector's loss of 1.17% and the S&P 500's loss of 5.73% in that time.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. The company is forecasted to report an EPS of $2.51, showcasing an 8.66% upward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $12.92 billion, up 4.94% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $12.30 per share and revenue of $59.52 billion, indicating changes of +21.54% and +5.66%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.02% lower. At present, AbbVie boasts a Zacks Rank of #3 (Hold).
Looking at its valuation, AbbVie is holding a Forward P/E ratio of 17.07. This expresses a premium compared to the average Forward P/E of 14.53 of its industry.
Also, we should mention that ABBV has a PEG ratio of 1.43. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.34.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 69, positioning it in the top 28% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.